{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:51:23Z","timestamp":1782449483241,"version":"3.54.5"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031663","name":"Saudi Food and Drug Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Chem."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Gabapentinoids, particularly pregabalin (PGL) and gabapentin (GBP), are widely used for neurological and psychiatric conditions but are increasingly linked to misuse and forensic challenges. Their high polarity, zwitterionic nature, and lack of strong chromophores present significant analytical challenges, often requiring derivatisation or specialised chromatographic systems. This study aimed to develop and validate a green, derivatisation-free HPLC-PDA method for the simultaneous determination of PGL and GBP in pharmaceutical formulations and seized samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Chromatographic separation was achieved on a Hypersil GOLD\u2122 C18 column (150 \u00d7 3\u00a0mm, 3\u00a0\u00b5m). An isocratic, highly aqueous mobile phase of water:methanol (96:4, v\/v) was used at a flow rate of 0.7\u00a0mL\/min. Detection was performed at 205\u00a0nm. Method optimisation was supported by a 2\n                      <jats:sup>3<\/jats:sup>\n                      full factorial design. The method was validated in accordance with International Council for Harmonisation Q2(R2) guidelines, including linearity, accuracy, precision, specificity, robustness, and sensitivity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The proposed method achieved effective separation without derivatisation, buffer systems, or specialised columns, while reducing organic solvent consumption compared to some reported methods. Calibration was linear over 5\u201360\u00a0\u03bcg\/mL (r \u2265 0.9997). Accuracy ranged from 95%\u2013103%. Intra- and inter-day precision (%RSD) values were below 5%. The limits of detection\/quantification values were 0.31\/1.03\u00a0\u03bcg\/mL for PGL and 0.25\/0.85\u00a0\u03bcg\/mL for GBP. Dissolution studies confirmed rapid drug release meeting pharmacopoeial criteria. Application to seized samples revealed PGL content exceeding labelled values (106%\u2013110%), while no peak corresponding to GBP was observed under the current HPLC-PDA conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The proposed method provides a simple, reliable, and environmentally favourable analytical approach for the simultaneous determination of gabapentinoids without complex sample preparation. Its successful application to pharmaceutical analysis, dissolution testing, and forensic samples highlights its suitability for routine laboratory use and regulatory monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fchem.2026.1845390","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:38:40Z","timestamp":1782448720000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A highly aqueous HPLC-PDA method for the assay of gabapentin and pregabalin: applications in pharmaceutical analysis, dissolution testing, and forensic screening"],"prefix":"10.3389","volume":"14","author":[{"given":"Fatimah M.","family":"Alamri","sequence":"first","affiliation":[{"name":"Department of Chemistry, College of Science, King Khalid University (KKU)","place":["Abha, Saudi Arabia"]},{"name":"Department of Chemistry, College of Science, University of Bisha (UB)","place":["Bisha, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taher","family":"Sahlabji","sequence":"additional","affiliation":[{"name":"Department of Chemistry, College of Science, King Khalid University (KKU)","place":["Abha, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya M.","family":"Alshehri","sequence":"additional","affiliation":[{"name":"Saudi Food and Drug Authority (SFDA)","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim A.","family":"Al Othaim","sequence":"additional","affiliation":[{"name":"Saudi Food and Drug Authority (SFDA)","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad S.","family":"Aldawasri","sequence":"additional","affiliation":[{"name":"Saudi Food and Drug Authority (SFDA)","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abubakr M.","family":"Idris","sequence":"additional","affiliation":[{"name":"Department of Chemistry, College of Science, King Khalid University (KKU)","place":["Abha, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1594567","DOI":"10.3389\/fchem.2025.1594567","article-title":"Investigation of illicit pregabalin in seized samples from Saudi Arabia","volume":"13","author":"Alamri","year":"2025","journal-title":"Front. Chem."},{"key":"B2","first-page":"1002","article-title":"Stereochemistry of gabapentin and several derivatives: solid state conformations and solution equilibria","volume":"85","author":"Ananda","year":"2003","journal-title":"Curr. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.18773\/austprescr.2023.025","article-title":"Gabapentinoids: a therapeutic review","volume":"46","author":"Athavale","year":"2023","journal-title":"Aust. Prescr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3390\/cryst14030257","article-title":"Exploring various crystal and molecular structures of gabapentin\u2014A review","volume":"14","author":"Baranowska","year":"2024","journal-title":"Crystals"},{"key":"B5","volume-title":"Gabapentin Capsules - British Pharmacopoeia","year":""},{"key":"B6","volume-title":"Pregabalin Capsules","year":""},{"key":"B7","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.jpba.2006.12.020","article-title":"Development and application of a validated HPLC method for the determination of gabapentin and its major degradation impurity in drug products","volume":"43","author":"Ciavarella","year":"2007","journal-title":"J. Pharm. Biomed. Analysis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/jat\/bkz070","article-title":"Validation of a high-throughput screening and quantification method for the determination of gabapentinoids in blood using a combination of LC-TOF-MS and LC-MS-MS","volume":"43","author":"De La Vega","year":"2019","journal-title":"J. Anal. Toxicol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.jpba.2010.04.008","article-title":"Liquid chromatographic separation of pregabalin and its possible impurities with fluorescence detection after postcolumn derivatization with o-phtaldialdehyde","volume":"53","author":"Dou\u0161a","year":"2010","journal-title":"J. Pharm. Biomed. Analysis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40265-017-0700-x","article-title":"Abuse and misuse of pregabalin and Gabapentin","volume":"77","author":"Evoy","year":"2017","journal-title":"Drugs"},{"key":"B11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.22159\/ajpcr.2018.v11i5.22256","article-title":"Development of a new stability indicating rp-hplc method for simultaneous estimation of epalrestat and pregabalin and its validation as per international conference on harmonization guidelines","volume":"11","author":"Goday","year":"2018","journal-title":"Asian J. Pharm. Clin. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"107926","DOI":"10.1016\/j.pharmthera.2021.107926","article-title":"The gabapentinoid drugs and their abuse potential","volume":"227","author":"Goins","year":"2021","journal-title":"Pharmacol. and Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jpba.2007.08.023","article-title":"Development and application of a validated HPLC method for the analysis of dissolution samples of Gabapentin drug products","volume":"46","author":"Gupta","year":"2008","journal-title":"J. Pharm. Biomed. Analysis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/1556-4029.13888","article-title":"Enantiomeric identification of pregabalin by GC\u2010MS via methylation and S\u2010TPC chiral derivatization","volume":"64","author":"Hitchcock","year":"2019","journal-title":"J. Forensic Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"jat;bkw070v1","DOI":"10.1093\/jat\/bkw070","article-title":"Gabapentin, pregabalin and vigabatrin quantification in human serum by GC\u2013MS after hexyl chloroformate derivatization","volume":"40","author":"Hlo\u017eek","year":"2016","journal-title":"J. Anal. Toxicol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1107\/S0108270101003341","article-title":"Gabapentin and gabapentin monohydrate","volume":"57","author":"Ibers","year":"2001","journal-title":"Acta Crystallogr. C Cryst. Struct. Commun."},{"key":"B17","volume-title":"ICH_Q2(R2)_Guideline_2023_1130","year":"2023"},{"key":"B18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/B978-0-12-822215-7.00023-8","article-title":"Pharmacology of analgesics","volume-title":"Anesthesia and Analgesia in Laboratory Animals","author":"Kendall","year":"2023"},{"key":"B19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.4103\/2322-1232.222561","article-title":"Reversed phase high performance liquid chromatographic method for simultaneous estimation of pregabalin and aceclofenac in tablet formulation (Acenac-N)","volume":"3","author":"Khanage","year":"2014","journal-title":"J. Rep. Pharma Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1080\/10739149.2013.876545","article-title":"Critical review on the analytical methods for the determination of zwitterionic antiepileptic drugs\u2014vigabatrin, pregabalin, and gabapentin\u2014in bulk and formulations","volume":"42","author":"Kosti\u0107","year":"2014","journal-title":"Instrum. Sci. and Technol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"20263","DOI":"10.1038\/s41598-025-07056-9","article-title":"Green and white analytical approach for parallel quantification of gabapentin and methylcobalamin in medicinal products using inventive RP-HPLC technique","volume":"15","author":"Mahgoub","year":"2025","journal-title":"Sci. Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1513597","DOI":"10.3389\/fpain.2024.1513597","article-title":"Pregabalin vs. gabapentin in the treatment of neuropathic pain: a comprehensive systematic review and meta-analysis of effectiveness and safety","volume":"5","author":"Mayoral","year":"2025","journal-title":"Front. Pain Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jpba.2012.05.001","article-title":"Development, validation and comparison of two microextraction techniques for the rapid and sensitive determination of pregabalin in urine and pharmaceutical formulations after ethyl chloroformate derivatization followed by gas chromatography\u2013mass spectrometric analysis","volume":"70","author":"Mudiam","year":"2012","journal-title":"J. Pharm. Biomed. Analysis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/jat\/bkx019","article-title":"Validated method for the screening and quantification of baclofen, gabapentin and pregabalin in human post-mortem whole blood using protein precipitation and liquid chromatography\u2013tandem mass spectrometry","volume":"41","author":"Nahar","year":"2017","journal-title":"J. Anal. Toxicol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1178221818801311","DOI":"10.1177\/1178221818801311","article-title":"Gabapentin for off-label use: evidence-based or cause for concern?","volume":"12","author":"Peckham","year":"2018","journal-title":"Subst. Abuse"},{"key":"B26","volume-title":"Appendix XII B: Dissolution Test for Solid Dosage Forms","author":"Pharmacopoeia Commission","year":"2025"},{"key":"B27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/9781118936979.ch45","article-title":"Pregabalin","volume-title":"The Treatment of Epilepsy","author":"Rheims","year":"2015"},{"key":"B28","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40263-014-0164-4","article-title":"Misuse and abuse of pregabalin and gabapentin: cause for concern?","volume":"28","author":"Schifano","year":"2014","journal-title":"CNS Drugs"},{"key":"B29","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1023\/A:1011976615750","article-title":"In vitro dissolution profile comparison\u2014statistics and analysis of the similarity factor, f2","volume":"15","author":"Shah","year":"1998","journal-title":"Pharm. Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1097\/j.pain.0000000000003240","article-title":"On the adverse effects of gabapentinoids","volume":"165","author":"Straube","year":"2024","journal-title":"Pain"},{"key":"B31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.clinthera.2007.01.013","article-title":"Pregabalin: a novel \u03b3-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders","volume":"29","author":"Tassone","year":"2007","journal-title":"Clin. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0920-1211(97)00084-3","article-title":"A summary of mechanistic hypotheses of Gabapentin pharmacology","volume":"29","author":"Taylor","year":"1998","journal-title":"Epilepsy Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"106492","DOI":"10.1016\/j.phrs.2022.106492","article-title":"Glutamatergic systems in neuropathic pain and emerging non-opioid therapies","volume":"185","author":"Temmermand","year":"2022","journal-title":"Pharmacol. Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"424","DOI":"10.4067\/S0717-97072009000400022","article-title":"Determination of gabapentin in bulk drug and in pharmaceutical dosage form by hplc method","volume":"54","author":"Udaykumar Rao","year":"2009","journal-title":"J. Chil. Chem. Soc."},{"key":"B35","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/chrsci\/49.6.417","article-title":"Highly sensitive determination and validation of Gabapentin in pharmaceutical preparations by HPLC with 4-Fluoro-7-Nitrobenzofurazan derivatization and fluorescence detection","volume":"49","author":"Ulu","year":"2011","journal-title":"J. Chromatogr. Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.59566\/IJBS.2009.5169","article-title":"A validated method without derivatization for the determination of gabapentin in bulk, pharmaceutical formulation and human urine samples","volume":"5","author":"Bassi","year":"2009","journal-title":"Int. J. Biomed. Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"116553","DOI":"10.1016\/j.trac.2022.116553","article-title":"AGREEprep \u2013 analytical greenness metric for sample preparation","volume":"149","author":"Wojnowski","year":"2022","journal-title":"TrAC Trends Anal. Chem."},{"key":"B38","article-title":"Gabapentin","volume-title":"StatPearls, Treasure Island (FL)","author":"Yasaei","year":"2025"}],"container-title":["Frontiers in Chemistry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2026.1845390\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:38:54Z","timestamp":1782448734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2026.1845390\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":38,"alternative-id":["10.3389\/fchem.2026.1845390"],"URL":"https:\/\/doi.org\/10.3389\/fchem.2026.1845390","relation":{},"ISSN":["2296-2646"],"issn-type":[{"value":"2296-2646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"article-number":"1845390"}}